If a injection to handle your HIV is a bit much for you, there may be other options soon. Although, Gilead's lenacapavir injection is sounding promising as a biannual option, it's still a shot. Not only is it an injection & very new, it's very expensive.
For those who don't handle injections well or whose insurance won't cover the bill, there might be another choice besides a daily regimen on the horizon. For many, a daily regimen has proven easier to handle than the multi-pill cocktail approach of the past. If that boosted adherence, then a weekly should do even better.
This piece details how Merck has recently developed Islatravir & has combined it with lenacapavir. Together they are being administered as weekly, oral option for handling HIV. The research looks promising. I have a feeling, most insurances are going to cover this before they consider the expense of Gilead's biannual lenacapavir injection.
There are new things coming to treat this virus. That's always good news. Give the article a read. Take care.
Cya...
No comments:
Post a Comment